Investors Invited to Join Class Action Against Rocket Pharmaceuticals for Alleged Fraud

On July 8, 2025, Levi & Korsinsky, LLP announced the initiation of a class action lawsuit on behalf of investors in Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT). The lawsuit claims that between February 27, 2025, and May 26, 2025, shareholders were misled due to the company’s failure to disclose important safety concerns regarding their drug, RP-A501.

According to the lawsuit's allegations, Rocket provided overwhelmingly optimistic statements to the public while simultaneously concealing material facts about the safety and clinical trial protocols related to RP-A501. Notably, it has been claimed that the company was aware of Serious Adverse Events (SAEs), which included the tragic death of a participant in the clinical trial, but failed to alert investors before the unfortunate incidents occurred. This lack of transparency, the lawsuit alleges, led to investors purchasing shares at artificially inflated prices.

The complaint highlights that Rocket made substantial changes to the clinical trial’s protocol, including the introduction of a novel immunomodulatory agent to the pretreatment regimen, without informing shareholders. This alteration was reportedly decided several months before it was disclosed, leaving investors unaware of its potential implications.

The turning point came on May 27, 2025, when Rocket announced that the FDA had put a clinical hold on the RP-A501 Phase 2 pivotal study due to a patient experiencing a severe adverse reaction. This news was devastating, resulting in a significant plunge in Rocket's stock, which fell from $6.27 per share to $2.33 per share in just one day, marking a staggering 37% decline.

As a potential class member, any investors who suffered losses during the specified period are encouraged to take action. There is an upcoming deadline of August 11, 2025, for shareholders to request appointment as lead plaintiff in this case, although participation in any recovery does not require a person to be designated as lead plaintiff.

Levi & Korsinsky assures potential class members that they may pursue compensation without incurring out-of-pocket costs, and there is no obligation to participate. The firm comes with a strong reputation, having secured hundreds of millions for clients in past securities litigation and earning recognition as a leading law firm in this field.

If you are interested in joining this class action suit or need more information, you can reach out to Joseph E. Levi, Esq. via email at [email protected] or call at (212) 363-7500. The firm has made it clear that they are dedicated to fighting for the rights of aggrieved investors and have extensive experience dealing with complex securities-related issues.

In summary, the class action against Rocket Pharmaceuticals highlights the need for transparency in corporate communications and the duty of companies to ensure investors are fully informed of the risks associated with their investments. Investors affected by Rocket’s alleged actions are strongly urged to explore their options before the deadline.